Titanium dioxide nanoparticles exacerbate DSS-induced colitis: Role of the NLRP3 inflammasome

Gut

Volumn 66, Issue 7, 2017, Pages 1216-1224

  Ruiz, Pedro A ^a   Morón, Belen ^a   Becker, Helen M ^a   Lang, Silvia ^a   Atrott, Kirstin ^a   Spalinger, Marianne R ^a   Scharl, Michael ^a   Wojtal, Kacper A ^a   Fischbeck Terhalle, Anne ^a   Frey Wagner, Isabelle ^a   Hausmann, Martin ^a   Kraemer, Thomas ^a   Rogler, Gerhard ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY MECHANISMS; INTESTINAL BARRIER FUNCTION; REACTIVE OXYGEN SPECIES

Indexed keywords

CRYOPYRIN; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; REACTIVE OXYGEN METABOLITE; TITANIUM DIOXIDE NANOPARTICLE; COLORING AGENT; DEXTRAN SULFATE; INFLAMMASOME; NANOPARTICLE; NLRP3 PROTEIN, MOUSE; TITANIUM; TITANIUM DIOXIDE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW DERIVED MACROPHAGE; CACO-2 CELL LINE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE RELEASE; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DISEASE EXACERBATION; FEMALE; HT-29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; SPLEEN; ULCERATIVE COLITIS; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; COLITIS; CYTOLOGY; DISEASE MODEL; EPITHELIUM CELL; IMMUNOLOGY; INTESTINE; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; PATHOLOGY;

ANIMALS; CASPASE 1; COLITIS; COLORING AGENTS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; HUMANS; INFLAMMASOMES; INTERLEUKIN-18; INTERLEUKIN-1BETA; INTESTINES; MACROPHAGES; MICE, INBRED C57BL; MICE, KNOCKOUT; NANOPARTICLES; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; REACTIVE OXYGEN SPECIES; SPLEEN; TITANIUM;

EID: 84958093561     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310297     Document Type: Article

References (57)

1. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011;474:298-306.
2. Scharl M, Rogler G. Inflammatory bowel disease pathogenesis: what is new? Curr Opin Gastroenterol 2012;28:301-9.
3. Rogler G. Interaction between susceptibility and environment: examples from the digestive tract. Dig Dis 2011;29:136-43.
4. Rogler G, Vavricka S. Exposome in IBD: recent insights in environmental factors that influence the onset and course of IBD. Inflamm Bowel Dis 2015;21:400-8.
5. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(Suppl 1):S3-9.
6. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004;126:1504-17.
7. Weir A, Westerhoff P, Fabricius L, et al. Titanium dioxide nanoparticles in food and personal care products. Environ Sci Technol 2012;46:2242-50.
8. EFSA. Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and materials in Contact with Food on a request from the Commission related to the safety in use of rutile titanium dioxide as an alternative to the presently permitted anatase form. EFSA J 2004;163:1-12.
9. Lomer MC, Hutchinson C, Volkert S, et al. Dietary sources of inorganic microparticles and their intake in healthy subjects and patients with Crohn's disease. Br J Nutr 2004;92:947-55.
10. [No authors listed]. Specifications for the identity and purity of food additives and their toxicological evaluation: some food colours, emulsifiers, stabilizers, anticaking agents, and certain other substances. Thirtenth report of the Joint FAO-WHO Expert Committee on Food Additives. Rome, 27 May-4 June 1969. World Health Organ Tech Rep Ser 1970;445:1-36.
11. European Parliament C. European Parliament and Council Directive 94/36/EC of 30 June 1994 on colours for use in foodstuffs Official Journal L 237 1994:13-29.
12. 2. Biol Trace Elem Res 2011;140:186-97.
13. Bermudez E, Mangum JB, Wong BA, et al. Pulmonary responses of mice, rats, and hamsters to subchronic inhalation of ultrafine titanium dioxide particles. Toxicol Sci 2004;77:347-57.
14. Trouiller B, Reliene R, Westbrook A, et al. Titanium dioxide nanoparticles induce DNA damage and genetic instability in vivo in mice. Cancer Res 2009;69:8784-9.
15. Wang JJ, Sanderson BJ, Wang H. Cyto- and genotoxicity of ultrafine TiO2 particles in cultured human lymphoblastoid cells. Mutat Res 2007;628:99-106.
16. Sohaebuddin SK, Thevenot PT, Baker D, et al. Nanomaterial cytotoxicity is composition, size, and cell type dependent. Part Fibre Toxicol 2010;7:22.
17. Baan R, Straif K, Grosse Y, et al. Carcinogenicity of carbon black, titanium dioxide, and talc. Lancet Oncol 2006;7:295-6.
18. Wang J, Zhou G, Chen C, et al. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol Lett 2007;168:176-85.
19. Borm PJ, Robbins D, Haubold S, et al. The potential risks of nanomaterials: a review carried out for ECETOC. Part Fibre Toxicol 2006;3:11.
20. Powell JJ, Ainley CC, Harvey RS, et al. Characterisation of inorganic microparticles in pigment cells of human gut associated lymphoid tissue. Gut 1996;38:390-5.
21. Lomer MC, Thompson RP, Powell JJ. Fine and ultrafine particles of the diet: influence on the mucosal immune response and association with Crohn's disease. Proc Nutr Soc 2002;61:123-30.
22. Franchi L, Eigenbrod T, Muñoz-Planillo R, et al. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 2009;10:241-7.
23. Yazdi AS, Guarda G, Riteau N, et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β. Proc Natl Acad Sci USA 2010;107:19449-54.
24. Villani AC, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 2009;41:71-6.
25. Mariathasan S, Weiss DS, Newton K, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006;440:228-32.
26. Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.
27. Franchi L, Muñoz-Planillo R, Nuñez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol 2012;13:325-32.
28. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008;9:847-56.
29. Dostert C, Pétrilli V, Van Bruggen R, et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008;320:674-7.
30. Obermeier F, Kojouharoff G, Hans W, et al. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol 1999;116:238-45.
31. Becker C, Fantini MC, Neurath MF. High resolution colonoscopy in live mice. Nat Protoc 2006;1:2900-4.
32. Hausmann M, Obermeier F, Paper DH, et al. In vivo treatment with the herbal phenylethanoid acteoside ameliorates intestinal inflammation in dextran sulphate sodium-induced colitis. Clin Exp Immunol 2007;148:373-81.
33. Wirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007;2:541-6.
34. Jaggi GP, Harlev M, Ziegler U, et al. Cerebrospinal fluid segregation optic neuropathy: an experimental model and a hypothesis. Br J Ophthalmol 2010;94:1088-93.
35. Obermeier F, Hausmann M, Kellermeier S, et al. IL-15 protects intestinal epithelial cells. Eur J Immunol 2006;36:2691-9.
36. Pittet V, Juillerat P, Mottet C, et al. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol 2009;38:922-31.
37. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
38. Rachmilewitz D. Coated mesazaline (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989;298:82-6.
39. Shinohara N, Danno N, Ichinose T, et al. Tissue distribution and clearance of intravenously administered titanium dioxide (TiO(2)) nanoparticles. Nanotoxicology 2014;8:132-41.
40. Chen J, Dong X, Zhao J, et al. In vivo acute toxicity of titanium dioxide nanoparticles to mice after intraperitioneal injection. J Appl Toxicol 2009;29:330-7.
41. Tschopp J, Schroder K. NLRP3 inflammasome activation: The convergence of multiple signalling pathways on ROS production? Nat Rev Immunol 2010;10:210-15.
42. Duan Y, Liu J, Ma L, et al. Toxicological characteristics of nanoparticulate anatase titanium dioxide in mice. Biomaterials 2010;31:894-9.
43. Jovanović B. Critical review of public health regulations of titanium dioxide, a human food additive. Integr Environ Assess Manag 2015;11:10-20.
44. Nogueira CM, de Azevedo WM, Dagli ML, et al. Titanium dioxide induced inflammation in the small intestine. World J Gastroenterol 2012;18:4729-35.
45. Bauer C, Duewell P, Mayer C, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010;59:1192-9.
46. Zaki MH, Boyd KL, Vogel P, et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 2010;32:379-91.
47. Hirota SA, Ng J, Lueng A, et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis 2011;17:1359-72.
48. Song-Zhao GX, Srinivasan N, Pott J, et al. Nlrp3 activation in the intestinal epithelium protects against a mucosal pathogen. Mucosal Immunol 2014;7:763-74.
49. Walczak AP, Fokkink R, Peters R, et al. Behaviour of silver nanoparticles and silver ions in an in vitro human gastrointestinal digestion model. Nanotoxicology 2013;7:1198-210.
50. Peters R, Kramer E, Oomen AG, et al. Presence of nano-sized silica during in vitro digestion of foods containing silica as a food additive. ACS Nano 2012;6: 2441-51.
51. Brun E, Barreau F, Veronesi G, et al. Titanium dioxide nanoparticle impact and translocation through ex vivo, in vivo and in vitro gut epithelia. Part Fibre Toxicol 2014;11:13.
52. Sang X, Fei M, Sheng L, et al. Immunomodulatory effects in the spleen-injured mice following exposure to titanium dioxide nanoparticles. J Biomed Mater Res A 2014;102:3562-72.
53. Geiser M, Rothen-Rutishauser B, Kapp N, et al. Ultrafine particles cross cellular membranes by nonphagocytic mechanisms in lungs and in cultured cells. Environ Health Perspect 2005;113:1555-60.
54. Mu Q, Hondow NS, Krzemiński L, et al. Mechanism of cellular uptake of genotoxic silica nanoparticles. Part Fibre Toxicol 2012;9:29.
55. 2 nanoparticles. PLoS ONE 2013;8:e62816.
56. Lomer MC, Harvey RS, Evans SM, et al. Efficacy and tolerability of a low microparticle diet in a double blind, randomized, pilot study in Crohn's disease. Eur J Gastroenterol Hepatol 2001;13:101-6.
57. Lomer MC, Grainger SL, Ede R, et al. Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn's disease. Eur J Gastroenterol Hepatol 2005;17:377-84.